MIRA Pharmaceuticals, Inc. Discusses Potential of Revolutionary THC Analog Drug, MIRA1a, with The Stock Day Podcast

<div>The Stock Day Podcast welcomed MIRA Pharmaceuticals, Inc.(Nasdaq:MIRA)(“the Company”), a pre-clinical-stage pharmaceutical development company developing a Novel synthetic THC analog. CEO of the Company, Erez Aminov, joined Stock Day host Kevin Davis following the company’s NASDAQ IPO.</div>